<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>8894349</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmid">35241697</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmc">8894349</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="publisher-id">285</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="doi">10.1038/s41531-022-00285-z</article-id></all-ids><extracted-table><table-id>Tab1</table-id><table-label>Table 1</table-label><table-caption>Demographic and clinical characteristics of the three study groups.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab1"><label>Table 1</label><caption><p>Demographic and clinical characteristics of the three study groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>NM-NC</th><th>GBA NM-MC</th><th>LRRK2 NM-MC</th><th><italic>p</italic>-value</th></tr></thead><tbody><tr><td>Age</td><td>53.55 ± 10.51</td><td>52.85 ± 8.81</td><td>50.52 ± 7.56</td><td>0.44<sup>a</sup></td></tr><tr><td>Gender (F/M)</td><td>18/16</td><td>12/14</td><td>13/12</td><td>0.91<sup>b</sup></td></tr><tr><td colspan="5">Handedness</td></tr><tr><td> ⁃ Right/left/ambidextrous</td><td>29/4/2</td><td>25/1/0</td><td>20/4/1</td><td>0.19<sup>c</sup></td></tr><tr><td>UPDRS-III</td><td>0.87 ± 1.26</td><td>0.61 ± 1.1</td><td>0.76 ± 2.05</td><td>0.86<sup>a</sup></td></tr><tr><td>UPDRS- Total</td><td>6.62 ± 5.32</td><td>4.50 ± 2.8</td><td>5.96 ± 5</td><td>0.26<sup>a</sup></td></tr><tr><td>MOCA</td><td>26.50 ± 2.68</td><td>26.69 ± 2.56</td><td>27.68 ± 2.68</td><td>0.28<sup>a</sup></td></tr><tr><td>UPSIT</td><td>31.39 ± 6.95</td><td>30.35 ± 7.42</td><td>37.12 ± 9.11</td><td>0.66<sup>a</sup></td></tr><tr><td>BDI</td><td>2.67 ± 6.21</td><td>5.28 ± 5.60</td><td>4.56 ± 4.77</td><td>0.08<sup>a</sup></td></tr><tr><td>SCOPA -AUT</td><td>7.03 ± 6.21</td><td>6.52 ± 7.00</td><td>7.18 ± 6.22</td><td>0.93<sup>a</sup></td></tr><tr><td>RBDq</td><td>2.00 ± 1.52</td><td>1.56 ± 2</td><td>1.43 ± 1.85</td><td>0.44<sup>a</sup></td></tr><tr><td>NMS</td><td>3.18 ± 3.20</td><td>2.80 ± 3.24</td><td>2.95 ± 1.92</td><td>0.88<sup>a</sup></td></tr><tr><td>LR</td><td>6.33 ± 17.00</td><td>11.38 ± 26.23</td><td>12.00 ± 26.00</td><td>0.57<sup>a</sup></td></tr><tr><td> ⁃ Low (&lt;70) [<italic>N</italic>, %]</td><td>34, 97%</td><td>24, 92%</td><td>23, 92%</td><td>–</td></tr><tr><td> ⁃ High (&gt;70) [<italic>N</italic>,%]</td><td>1, 3%</td><td>2, 8%</td><td>2, 8%</td><td>–</td></tr></tbody></table><table-wrap-foot><p>Unless otherwise stated, all values are expressed as mean ± SD.</p><p><sup>a</sup>1 × 3 ANOVA.</p><p><sup>b</sup><italic>χ</italic><sup>2</sup> test.</p><p><sup>c</sup>Kruskal-Wallis test. <italic>H&amp;Y</italic> Hohen &amp; Yahr stage, <italic>UPDRS</italic> Unified Parkinson’s disease rating scale, <italic>MOCA</italic> Montreal cognitive assessment. <italic>UPSIT</italic> university of Pennsylvania smell identification test, <italic>BDI</italic> Beck’s depression inventory, <italic>SCOPA-AUT</italic> Scale of Outcome in Parkinson’s disease Autonomic Dysfunction questionnaire, <italic>RBDq</italic> REM sleep behavior disorder questionnaire, <italic>NMS</italic> nonmotor symptoms questionnaire, <italic>LR</italic> likelihood ratio.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Demographic and clinical characteristics of the three study groups.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th/><th>NM-NC</th><th>GBA NM-MC</th><th>LRRK2 NM-MC</th><th>p-value</th></tr></thead><tbody><tr><td>Age</td><td>53.55 ± 10.51</td><td>52.85 ± 8.81</td><td>50.52 ± 7.56</td><td>0.44a</td></tr><tr><td>Gender (F/M)</td><td>18/16</td><td>12/14</td><td>13/12</td><td>0.91b</td></tr><tr><td colspan="5">Handedness</td></tr><tr><td> ⁃ Right/left/ambidextrous</td><td>29/4/2</td><td>25/1/0</td><td>20/4/1</td><td>0.19c</td></tr><tr><td>UPDRS-III</td><td>0.87 ± 1.26</td><td>0.61 ± 1.1</td><td>0.76 ± 2.05</td><td>0.86a</td></tr><tr><td>UPDRS- Total</td><td>6.62 ± 5.32</td><td>4.50 ± 2.8</td><td>5.96 ± 5</td><td>0.26a</td></tr><tr><td>MOCA</td><td>26.50 ± 2.68</td><td>26.69 ± 2.56</td><td>27.68 ± 2.68</td><td>0.28a</td></tr><tr><td>UPSIT</td><td>31.39 ± 6.95</td><td>30.35 ± 7.42</td><td>37.12 ± 9.11</td><td>0.66a</td></tr><tr><td>BDI</td><td>2.67 ± 6.21</td><td>5.28 ± 5.60</td><td>4.56 ± 4.77</td><td>0.08a</td></tr><tr><td>SCOPA -AUT</td><td>7.03 ± 6.21</td><td>6.52 ± 7.00</td><td>7.18 ± 6.22</td><td>0.93a</td></tr><tr><td>RBDq</td><td>2.00 ± 1.52</td><td>1.56 ± 2</td><td>1.43 ± 1.85</td><td>0.44a</td></tr><tr><td>NMS</td><td>3.18 ± 3.20</td><td>2.80 ± 3.24</td><td>2.95 ± 1.92</td><td>0.88a</td></tr><tr><td>LR</td><td>6.33 ± 17.00</td><td>11.38 ± 26.23</td><td>12.00 ± 26.00</td><td>0.57a</td></tr><tr><td> ⁃ Low (&lt;70) [N, %]</td><td>34, 97%</td><td>24, 92%</td><td>23, 92%</td><td>–</td></tr><tr><td> ⁃ High (&gt;70) [N,%]</td><td>1, 3%</td><td>2, 8%</td><td>2, 8%</td><td>–</td></tr></tbody></table></div>Unless otherwise stated, all values are expressed as mean ± SD.a1 × 3 ANOVA.bχ2 test.cKruskal-Wallis test. H&amp;Y Hohen &amp; Yahr stage, UPDRS Unified Parkinson’s disease rating scale, MOCA Montreal cognitive assessment. UPSIT university of Pennsylvania smell identification test, BDI Beck’s depression inventory, SCOPA-AUT Scale of Outcome in Parkinson’s disease Autonomic Dysfunction questionnaire, RBDq REM sleep behavior disorder questionnaire, NMS nonmotor symptoms questionnaire, LR likelihood ratio.</transformed-table></extracted-table><extracted-table><table-id>Tab2</table-id><table-label>Table 2</table-label><table-caption>Measured DaTscan striatal binding ratio (SBR) and rs-fMRI functional connectivity (FC) values within striatal regions of interest (ROIs).</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab2"><label>Table 2</label><caption><p>Measured DaTscan striatal binding ratio (SBR) and rs-fMRI functional connectivity (FC) values within striatal regions of interest (ROIs).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th rowspan="2">NM-NC</th><th rowspan="2">GBA-NMC</th><th rowspan="2">LRRK2-NMC</th><th rowspan="2"><italic>p</italic> value</th><th colspan="3">Post-hoc comparisons</th></tr><tr><th>NM-NC <italic>vs</italic>. GBA-NMC</th><th>NM-NC <italic>vs</italic>. LRRK2-NMC</th><th>GBA-NMC <italic>vs</italic>. LRRK2-NMC</th></tr></thead><tbody><tr><td colspan="8"><bold><italic>a. DaT- SBR</italic></bold></td></tr><tr><td><bold>L Caudate</bold></td><td>3.21 ± 0.38</td><td>3.21 ± 0.53</td><td>3.07 ± 0.46</td><td>0.481<sup>a</sup></td><td>–</td><td>–</td><td>–</td></tr><tr><td><bold>R Caudate</bold></td><td>3.17 ± 0.38</td><td>3.08 ± 0.52</td><td>3.07 ± 0.45</td><td>0.62<sup>a</sup></td><td>–</td><td>–</td><td>–</td></tr><tr><td><bold>L Putamen</bold></td><td>3.50 ± 0.44</td><td>3.48 ± 0.52</td><td>3.30 ± 0.50</td><td>0.31<sup>a</sup></td><td>–</td><td>–</td><td>–</td></tr><tr><td><bold>R Putamen</bold></td><td>3.39 ± 0.34</td><td>3.36 ± 0.52</td><td>3.08 ± 0.40</td><td>0.028<sup>a</sup></td><td>–</td><td>0.037<sup>b</sup></td><td>–</td></tr><tr><td><bold>Caudate asymmetry [%]</bold></td><td>3.68 ± 3.96</td><td>5.44 ± 4.91</td><td>5.38 ± 4.63</td><td>0.51<sup>a</sup></td><td>–</td><td>–</td><td>–</td></tr><tr><td><bold>Putamen asymmetry[%]</bold></td><td>6.41 ± 4.88</td><td>6.24 ± 5.46</td><td>9.35 ± 10.15</td><td>0.24<sup>a</sup></td><td>–</td><td>–</td><td>–</td></tr><tr><td colspan="8"><bold><italic>b. rs-fMRI-FC</italic></bold></td></tr><tr><td><bold>L Caudate</bold></td><td>3.12 ± 1.01</td><td>2.92 ± 0.85</td><td>3.87 ± 2.57</td><td>0.15<sup>a</sup></td><td>–</td><td>–</td><td>–</td></tr><tr><td><bold>R Caudate</bold></td><td>3.12 ± 1.01</td><td>2.82 ± 0.85</td><td>3.72 ± 2.37</td><td>0.14<sup>a</sup></td><td>–</td><td>–</td><td>–</td></tr><tr><td><bold>L Putamen</bold></td><td>2.61 ± 1.24</td><td>2.04 ± 0.82</td><td>3.04 ± 2.32</td><td>0.12<sup>a</sup></td><td>–</td><td>–</td><td>–</td></tr><tr><td><bold>R Putamen</bold></td><td>2.33 ± 1.22</td><td>1.84 ± 0.88</td><td>2.93 ± 2.11</td><td>0.05<sup>a</sup></td><td>–</td><td>–</td><td>0.05<sup>b</sup></td></tr></tbody></table><table-wrap-foot><p>Unless otherwise stated, all values are expressed as mean ± SD.</p><p><sup>a</sup>1 × 3 ANOVA.</p><p><sup>b</sup>Post-hoc comparisons (Bonferroni-corrected).</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Measured DaTscan striatal binding ratio (SBR) and rs-fMRI functional connectivity (FC) values within striatal regions of interest (ROIs).</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th rowspan="2">NM-NC</th><th rowspan="2">GBA-NMC</th><th rowspan="2">LRRK2-NMC</th><th rowspan="2">p value</th><th colspan="3">Post-hoc comparisons</th></tr><tr><th>NM-NC vs. GBA-NMC</th><th>NM-NC vs. LRRK2-NMC</th><th>GBA-NMC vs. LRRK2-NMC</th></tr></thead><tbody><tr><td colspan="8">a. DaT- SBR</td></tr><tr><td>L Caudate</td><td>3.21 ± 0.38</td><td>3.21 ± 0.53</td><td>3.07 ± 0.46</td><td>0.481a</td><td>–</td><td>–</td><td>–</td></tr><tr><td>R Caudate</td><td>3.17 ± 0.38</td><td>3.08 ± 0.52</td><td>3.07 ± 0.45</td><td>0.62a</td><td>–</td><td>–</td><td>–</td></tr><tr><td>L Putamen</td><td>3.50 ± 0.44</td><td>3.48 ± 0.52</td><td>3.30 ± 0.50</td><td>0.31a</td><td>–</td><td>–</td><td>–</td></tr><tr><td>R Putamen</td><td>3.39 ± 0.34</td><td>3.36 ± 0.52</td><td>3.08 ± 0.40</td><td>0.028a</td><td>–</td><td>0.037b</td><td>–</td></tr><tr><td>Caudate asymmetry [%]</td><td>3.68 ± 3.96</td><td>5.44 ± 4.91</td><td>5.38 ± 4.63</td><td>0.51a</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Putamen asymmetry[%]</td><td>6.41 ± 4.88</td><td>6.24 ± 5.46</td><td>9.35 ± 10.15</td><td>0.24a</td><td>–</td><td>–</td><td>–</td></tr><tr><td colspan="8">b. rs-fMRI-FC</td></tr><tr><td>L Caudate</td><td>3.12 ± 1.01</td><td>2.92 ± 0.85</td><td>3.87 ± 2.57</td><td>0.15a</td><td>–</td><td>–</td><td>–</td></tr><tr><td>R Caudate</td><td>3.12 ± 1.01</td><td>2.82 ± 0.85</td><td>3.72 ± 2.37</td><td>0.14a</td><td>–</td><td>–</td><td>–</td></tr><tr><td>L Putamen</td><td>2.61 ± 1.24</td><td>2.04 ± 0.82</td><td>3.04 ± 2.32</td><td>0.12a</td><td>–</td><td>–</td><td>–</td></tr><tr><td>R Putamen</td><td>2.33 ± 1.22</td><td>1.84 ± 0.88</td><td>2.93 ± 2.11</td><td>0.05a</td><td>–</td><td>–</td><td>0.05b</td></tr></tbody></table></div>Unless otherwise stated, all values are expressed as mean ± SD.a1 × 3 ANOVA.bPost-hoc comparisons (Bonferroni-corrected).</transformed-table></extracted-table></extracted-tables-set>